Tominaga T, Abe O, Ohshima A, Hayasaka H, Uchino J, Abe R, Enomoto K, Izuo M, Watanabe H, Takatani O
Department of Surgery, Tokyo Metropolitan Komagome Hospital, Japan.
Eur J Cancer. 1994;30A(7):959-64. doi: 10.1016/0959-8049(94)90123-6.
The usefulness of CAF [cyclophosphamide (CPA)/doxorubicin (ADR)/5-fluorouracil (5-FU)] + medroxyprogesterone acetate (MPA) therapy for advanced/recurrent breast cancer was studied in a randomised trial at 56 institutions. Patients received CAF therapy [CPA: 100 mg, orally, days 1-14; ADR: 30 mg/m2, intravenously (i.v.), days 1 and 8; 5-FU: 500 mg/m2, i.v., days 1 and 8) in arm I, or CAF + MPA therapy (CAF + MPA 1200 mg, daily) in arm II. The response rate was significantly higher (P = 0.041) in arm II (53.5%, 46/86) than arm I (36.6%, 30/82). The response rate by tumour site was significantly higher for lymph node and bone lesions in arm II. Partial response duration and overall response duration were significantly longer in arm II. Incidences of anorexia and nausea/vomiting were significantly higher in arm I but in arm II, moon face, oedema and vaginal bleeding were significantly higher. Many patients in arm II demonstrated improvement in performance status and weight loss, suggesting a beneficial effect of MPA. The chemoendocrine therapy with CAF + MPA appears to be more beneficial than CAF alone in the treatment of advanced/recurrent breast cancer.
在56家机构开展的一项随机试验中，研究了环磷酰胺（CPA）/多柔比星（ADR）/5-氟尿嘧啶（5-FU）（CAF）联合醋酸甲羟孕酮（MPA）治疗晚期/复发性乳腺癌的疗效。I组患者接受CAF治疗（CPA：100mg，口服，第1 - 14天；ADR：30mg/m²，静脉注射，第1天和第8天；5-FU：500mg/m²，静脉注射，第1天和第8天），II组患者接受CAF + MPA治疗（CAF + MPA 1200mg，每日）。II组的缓解率（53.5%，46/86）显著高于I组（36.6%，30/82）（P = 0.041）。II组中，淋巴结和骨转移灶的肿瘤部位缓解率显著更高。II组的部分缓解持续时间和总缓解持续时间显著更长。I组的厌食和恶心/呕吐发生率显著更高，但II组的满月脸、水肿和阴道出血发生率显著更高。II组的许多患者表现出身体状况改善和体重减轻，提示MPA有有益作用。在晚期/复发性乳腺癌的治疗中，CAF + MPA的化疗内分泌治疗似乎比单纯CAF更有益。
